Chemically programmable immunity

Details Chemically programmable immunity Chemically programmable immunity

2003-10-29

2008-09-09

Saunders, David A (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S093100, C424S134100, C424S192100, C424S193100

Reexamination Certificate

active

07422746

ABSTRACT:
Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

REFERENCES:
patent: 4169137 (1979-09-01), Hirschfeld et al.
patent: 4243749 (1981-01-01), Sadeh et al.
patent: 4737453 (1988-04-01), Primus
patent: 4940670 (1990-07-01), Rhodes
patent: 5017558 (1991-05-01), Vyas
patent: 5204449 (1993-04-01), Puri
patent: 5378815 (1995-01-01), Krsmanovic et al.
patent: 5869232 (1999-02-01), Sällberg
patent: 6040137 (2000-03-01), Sällberg
patent: 6245895 (2001-06-01), Sällberg
patent: 6660842 (2003-12-01), Sällberg
patent: 6933366 (2005-08-01), Sallberg et al.
patent: 7033594 (2006-04-01), Low et al.
patent: 2001/0031252 (2001-10-01), Low et al.
patent: 2003/0108555 (2003-06-01), Marinkovich
patent: 2004/0146515 (2004-07-01), Mullis
patent: 2006/0002891 (2006-01-01), Pouletty
patent: 0 429 816 (1990-10-01), None
patent: WO 92/08491 (1992-05-01), None
patent: WO 95/29938 (1995-11-01), None
patent: WO 97/37690 (1997-10-01), None
patent: WO 01/32207 (2001-05-01), None
Alexander, H. et al.; “Altering the antigenicity of proteins”;Proc. Natl. Acad. Sci. USA,vol. 89, pp. 3352-3356, Apr. 1992.
Geysen, H. Mario et al.; “Isotope or mass encoding of combinatorial libraries”;Chemistry&Biology;1996, vol. 3, No. 8, pp. 679-688.
Edmundson, Allen B. et al.; “Binding of peptides to proteins: an exercise in molecular design”;1991 Host-guest molecular interactions: from chemistry to biology. Wiley, Chichester (Ciba Foundation Symposium 158);pp. 213-230.
Smith, George; “Surface presentation of protein epitopes using bacteriophage expression systems”;Current Biology Ltd.,ISSN 0958-1669; pp. 668-673.
Rodda, Stuart J. et al.; “Multipin Technology in the Preparation and Screening of Peptide Libraries”;Australasian Biotechnology 3,pp. 346-347 (1993).
Carter, J. Mark; “Epitope Mapping of a Protein Using the Geysen (PEPSCAN) Procedure”;Methods in Molecular Biologyvol. 36:Peptide Analysis Protocols;pp. 207-223 (1994).
Gyesen, H. Mario et al.; “Strategies for epitope analysis using peptide synthesis”;Journal of Immunological Methods,102 (1987) 259-274.
Geysen, H. Mario et al.; “Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid”;Proceedings of the National Academy of Sciences of the United States of America;vol. 81, No. 13, [Part 1: Biological Sciences] (Jul. 1, 1984), 3998-4002.
Schultz, Jane S. et al.; “The Combinatorial Library: A Multifunctional Resource”;Biotechnol. Prog.,1996, 12, 729-743.
Edmundson, A.B. et al.; “Principles and Pitfalls in Designing Site-Directed Peptide Ligands”;Proteins: Structure, Function and Genetics;16:246-267 (1993).
Valerio, Robert M. et al.; “Multipin peptide synthesis at the micromole scale using 2-hydroxyethyl methacrylate grated polyethylene supports”;Int. J. peptide Protein Res.42, 1993, 1-9.
Tribbick, Gordon et al.; “Systematic fractionation of serum antibodies using multiple antigen homologous peptides as affinity ligands”;Journal of Immunological Methods,139, (1991) 155-166.
Galili, Uri et al.; “α-Gal and Anti-Gal α1,3-Galactosyltransferase, α-Gal Epitopes, and the Natural Anti-Gal Antibody”;Subcellular Biochemistry;vol. 32, 1999, pp. 1-23.
Wagner, D.S.; “Ratio Encoding Combinatorial Libraries with Stable Isotopes and their Utility in Pharmaceutical Research”;Combinatorial Chemistry&High Throughput Screening,1998, 1, 143-153.
Janczuk, A. et al.; “a-Gal Oligosaccharides: Chemistry and Potential Biomedical Application”;Current Medicinal Chemistry;1999, vol. 6, pp. 155-164.
Bruno, John G. et al.; “In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection”;Biosensors&Bioelectronics14 (1999), pp. 457-464.
Ahnert-Hilger, G. et al.; “Monoclonal Antibodies Against Tetanus Toxin and Toxoid”;Med Microbiol Immunol;(1983) 172:123-135.
Finberg, Robert W. et al.; “The Use of Antiidiotypic Antibodies as Vaccines Against Infectious Agents”;CRC Critical Reviews in Immunology;vol. 7, Issue 4, (1987); pp. 269-284.
Glennie, Martin J. et al.; “Preparation and Performance of Bispecific (F(ab′γ)2Antibody Containing Thioether-Linked Fab′γ Fragments”;Journal of Immunology;vol. 139, No. 7, Oct. 1, 1987, pp. 2367-2370.
Jayasena, Sumedha D.; “Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics”;Clinical Chemistry;vol. 45; No. 9; (1999) pp. 1628-1650.
Ringquist, Steven et al.; “Anti-L-Selectin Oligonucleotide Ligands Recognize CD62L-Positive Leukocytes: Binding Affinity and Specificity of Univalent and Bivalent Ligands”;Cytometry;vol. 33, 1998; pp. 394-405.
Colas, Pierre et al.; “Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2”;Nature;vol. 380; Apr. 11, 1996; pp. 548-550.
Weiner, George J. et al.; “Bispecific Anti-Idiotype/Anti-CD3 Antibody Therapy of Murine B Cell Lymphoma”;The Journal of Immunology;vol. 147, No. 11, Dec. 1, 1991, pp. 4035-4044.
Xu, Wei et al.; “Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope”;Proc. Natl. Acad. Sci. USA;vol. 93, Jul. 1996, pp. 7475-7480.
Richard C. Conrad et al.; “In Vitro Selection of Nucleic Acid Aptamers That Bind Proteins”;Methods in Enzymology,vol. 267, 1996, pp. 336-367.
Tim Fitzwater et al.; “A Selex Primer”;Methods in Enzymology,vol. 267, 1996, pp. 275-301.

Affiliated with

Also associated with

Rating

Chemically programmable immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemically programmable immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically programmable immunity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3968272